Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On January 4, 2017, Titan Pharmaceuticals, Inc. (the Company)
announced the appointment of Scott A. Smith and Rajinder Kumar to
the Companys Board of Directors.
Mr. Smith (54) has served in various management capacities with
Celgene Corporation since 2008, including as President,
Inflammation and Immunology since August 2014. From 2003 to 2008,
he served in various executive capacities with Biovail
Pharmaceuticals, Inc. and prior thereto spent 16 years Pharmacia
Upjohn Company. Mr. Smith holds a BSc in Chemistry and Biology
and an HBSc in Pharmacology and Toxicology from the University of
Western Ontario and a Masters in International Management from
the American Graduate School of International Management in
Arizona.
Dr. Kumar (62) has served as the Chairman and Chief Executive
Officer of MeRaD Pharmaceutical Ltd. in Cambridge U.K. since May
2009. He has also served as President and Chief Medical Officer
of Vitas Pharma in Hyderabad, India since he founded such company
in 2010. For the decade prior to joining MeRaD, he served in
various executive capacities with Dr. Reddys Labs, Ranbaxy
Laboratories Limited, Synaptic Pharmaceutical LLP and Glaxo
SmithKline Beecham. Dr. Kumar is a member of scientific advisory
boards in neuroscience, anti-infectives and metabolic disorders
He received a B.S. in Human Biology from the University of
London, a Masters in Ethology from the University of Birmingham,
a MBChB in Medicine from the University of Dundee and an advanced
diploma in Psychological Medicine from The Royal College of
Surgeons and Physicians in Ireland.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference
Item9.01. Financial Statement and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated January 4, 2017 |
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Recent Trading Information
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) closed its last trading session up +0.13 at 4.78 with 242,722 shares trading hands.
